Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study.
Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Okamoto W, Kawaoka T, Tsuge M, Hiramatsu A, Miki D, Imamura M, Takahashi S, Chayama K, Aikata H. Nagaoki Y, et al. Among authors: teraoka y. BMC Gastroenterol. 2021 Jul 31;21(1):306. doi: 10.1186/s12876-021-01884-5. BMC Gastroenterol. 2021. PMID: 34332532 Free PMC article.
Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
Nakamura Y, Imamura M, Kawakami Y, Teraoka Y, Daijo K, Honda F, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Chayama K. Nakamura Y, et al. Among authors: teraoka y. J Med Virol. 2017 Apr;89(4):665-671. doi: 10.1002/jmv.24679. Epub 2016 Oct 24. J Med Virol. 2017. PMID: 27602542
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Kawaoka T, Aikata H, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Kobayashi T, Nagaoki Y, Nakahara T, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K. Kawaoka T, et al. Among authors: teraoka y. Oncology. 2017;92(6):335-346. doi: 10.1159/000458532. Epub 2017 Mar 1. Oncology. 2017. PMID: 28245484
Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis.
Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, Hatooka M, Morio K, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Nagaoki Y, et al. Among authors: teraoka y. Hepatol Res. 2018 Jan;48(1):51-58. doi: 10.1111/hepr.12895. Epub 2017 Apr 27. Hepatol Res. 2018. PMID: 28342265
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Masuda K, et al. Among authors: teraoka y. J Gastroenterol. 2018 Jan;53(1):107-118. doi: 10.1007/s00535-017-1348-8. Epub 2017 May 4. J Gastroenterol. 2018. PMID: 28474222
Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury.
Morio K, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Nelson Hayes C, Tsugawa K, Yokozaki M, Chayama K. Morio K, et al. Among authors: teraoka y. J Gastroenterol. 2017 Dec;52(12):1252-1257. doi: 10.1007/s00535-017-1345-y. Epub 2017 May 5. J Gastroenterol. 2017. PMID: 28477171
Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma.
Teraoka Y, Kimura T, Aikata H, Daijo K, Osawa M, Honda F, Nakamura Y, Morio K, Morio R, Hatooka M, Kobayashi T, Nakahara T, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Nagata Y, Chayama K. Teraoka Y, et al. Hepatol Res. 2018 Feb;48(2):193-204. doi: 10.1111/hepr.12916. Epub 2017 Jun 24. Hepatol Res. 2018. PMID: 28544062
Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Masuda K, et al. Among authors: teraoka y. J Gastroenterol. 2018 Jan;53(1):161-162. doi: 10.1007/s00535-017-1352-z. J Gastroenterol. 2018. PMID: 28555325 No abstract available.
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Aikata H, Hayes CN, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K. Kan H, et al. Among authors: teraoka y. J Med Virol. 2017 Nov;89(11):1963-1972. doi: 10.1002/jmv.24885. Epub 2017 Jul 25. J Med Virol. 2017. PMID: 28657143
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H, Chayama K. Nagaoki Y, et al. Among authors: teraoka y. PLoS One. 2017 Aug 10;12(8):e0182710. doi: 10.1371/journal.pone.0182710. eCollection 2017. PLoS One. 2017. PMID: 28797106 Free PMC article.
122 results